Growth factor biotech Scholar Rock sets terms for $75 million IPO
Scholar Rock Holding, a preclinical biotech targeting growth factor inhibition for a variety of diseases, announced terms for its IPO on Monday.
The Cambridge, MA-based company plans to raise $75 million by offering 5.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Scholar Rock would command a fully diluted market value of $350 million.
Scholar Rock Holding was founded in 2012 and plans to list on the Nasdaq under the symbol SRRK. Jefferies, Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of May 21, 2018.
The article Growth factor biotech Scholar Rock sets terms for $75 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.